Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

482
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
482
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Intensive care medicine·2026
Same author

Increasing TET Expression and 5-Hydroxymethylcytosine Formation by a Carbocyclic 5-Aza-2'-deoxy-cytidine Antimetabolite.

Angewandte Chemie (International ed. in English)·2026
Same author

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Leukemia·2026
Same author

Association between depressive symptoms and atherosclerotic cardiovascular disease: a Swedish population-based cohort study.

BMC cardiovascular disorders·2026
Same author

AI-based hematological malignancy prediction from peripheral blood smears in a large diagnostic laboratory cohort.

Leukemia·2026
Same author

[Recognizing, classifying, and treating thrombocytopenia].

MMW Fortschritte der Medizin·2026

Related Experiment Video

Updated: Aug 30, 2025

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.3K

[Acute Myeloid Leukemia - Update 2022].

Christian Rausch1, Wolfgang Hiddemann1, Michael von Bergwelt-Baildon1

  • 1Medizinische Klinik und Poliklinik III, Klinikum der Universität München, LMU München, München, Deutschland.

Deutsche Medizinische Wochenschrift (1946)
|August 28, 2022
PubMed
Summary
This summary is machine-generated.

Acute myeloid leukemia (AML) diagnosis requires rapid workup. New targeted therapies and maintenance treatments are improving prognosis and enabling personalized treatment strategies, especially for older patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

233
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K

Related Experiment Videos

Last Updated: Aug 30, 2025

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

233
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) is a hematological emergency requiring prompt diagnosis and risk stratification.
  • Acute promyelocytic leukemia (APL) differentiation is critical due to high early mortality from thrombotic and bleeding complications.
  • Therapeutic landscape for AML is evolving with new drug approvals and targeted agents.

Purpose of the Study:

  • To provide an overview of current diagnostic and therapeutic approaches for AML.
  • To highlight the importance of rapid immunophenotypic and genetic characterization for risk stratification and treatment selection.
  • To discuss the impact of novel therapies on AML management and patient outcomes.

Main Methods:

  • Review of current diagnostic protocols for AML, emphasizing rapid workup.
  • Analysis of established and novel therapeutic strategies, including intensive induction, targeted agents, and chemotherapy-free regimens.
  • Discussion of post-remission and maintenance therapies, including targeted agents and oral azacitidine.

Main Results:

  • New targeted agents like Gemtuzumab-Ozogamicin and Midostaurin, along with liposomal chemotherapy CPX-351, are integrated into AML treatment.
  • Chemotherapy-free regimens with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are standard for most APL cases.
  • Maintenance therapies, such as Midostaurin and sorafenib, and oral azacitidine, are crucial for long-term remission.

Conclusions:

  • Modern AML therapy is increasingly individualized, driven by genetic aberrations and improved by new drugs.
  • Novel therapeutic approaches have significantly enhanced prognosis, particularly for older patients.
  • Continued advancements in understanding AML biology will further refine treatment options and improve outcomes.